N19 Insurance Policy Changes

ICD-10 N19 is officially defined as "Unspecified kidney failure." code N19 is referenced in 12 tracked payer policy changes from Harvard Pilgrim Health Care, Horizon BCBS NJ, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code N19 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Harvard Pilgrim Health Care · Effective Jul 1, 2026High impact
Change in denial process for lack of prior authorization
Point32Health has implemented a cascading denial policy: when a primary service is denied for lack of prior authorization, untimely authorization, or failure to meet medical necessity criteria, ALL related ancillary services, supporting services, procedures, and medications billed on the same or separate claims will also be denied. This policy is effective immediately for most Point32Health products (July 1, 2026) and will take effect September 1, 2026 for Harvard Pilgrim Health Care Commercial, with specific exceptions for radiology professional components, anesthesia, ambulance, pathology professional components, and pre/post services outside the date of service.
Horizon BCBS NJ · Effective Jan 1, 2026High impact
Statin Use in Persons with Diabetes (SUPD)
This is a new Medicare Part D Star Ratings measure (SUPD) effective for 2026 that evaluates whether patients ages 40-75 with diabetes on antidiabetic medications are also receiving statin therapy. Billing teams must ensure proper documentation and ICD-10 coding of exclusionary diagnoses to accurately track eligible patients and avoid measure performance penalties. Claims must include appropriate exclusion codes when patients have contraindications to statin therapy.
Capital Blue Cross · Effective Apr 1, 2026Medium impact
AB2026-04-002 Medicare only
Capital Blue Cross updated Medicare Part D Star measures for 2026, adding new exclusions for Statin Use in Persons with Diabetes (SUPD) that recognize PCSK9 inhibitors and bempedoic acid as alternatives for patients who cannot tolerate statins. Providers must submit specific ICD-10-CM codes annually during in-person or audio/video visits to qualify patients for exclusions from the SUPD measure.
Aetna · Identified Nov 4, 2026Medium impact
Selected Kidney Function Tests (CPB 0775, reviewed 2026-10-28)
Aetna's Clinical Policy Bulletin 0775 (reviewed 2026-10-28) designates multiple advanced kidney function tests as experimental, investigational, or unproven, including KidneyIntelX, IntelxDKD, NaviDKD, PromarkerD, RenalVysion, RenaDx, RenaXome, GFR NMR, APOL1 genotyping, and transdermal pyrazine-based GFR measurement. Claims for these tests will be denied when billed with the specified CPT codes and ICD-10 indications listed in the policy.
Aetna · Identified Oct 2, 2026Medium impact
Cardiovascular Monitoring Equipment for Home Use: Pulse, Blood Pressure, Telemonitors, and Pacemaker Monitors (CPB 0548, reviewed 2026-08-21)
Aetna considers validated home blood pressure monitors medically necessary as an alternative to ambulatory blood pressure monitoring to confirm hypertension in members age 18 and older with office readings greater than 140 systolic or 90 diastolic. Validated blood pressure monitors are considered medically necessary for members receiving hemodialysis or peritoneal dialysis in the home, and validated blood pressure cuffs are considered medically necessary durable medical equipment for members with hypertension. Self-contained pacemaker monitors, including audible and visible signal monitors, digital electronic monitors, and a specialized telephone attachment for trans-telephonic transmission of results, are considered medically necessary for members with cardiac pacemakers. Automated oscillometer serial blood pressure monitors for home use, AngelMed Guardian, CardioMEMS pillow and components, home and implantable congestive heart failure monitors, implantable inferior vena cava sensors, implantable wireless pulmonary artery pressure monitors for heart failure, Zoll Heart Failure and Arrhythmia Management System, bioelectrical impedance analysis, and non-invasive central blood pressure assessment with SphygmoCor are considered experimental, investigational, or unproven. Pulse tachometers do not meet Aetna's definition of covered durable medical equipment.
Aetna · Identified Aug 16, 2026Medium impact
Selected Kidney Function Tests (CPB 0775, reviewed 2026-07-31)
Aetna considers these kidney function tests experimental, investigational, or unproven because their effectiveness has not been established: APOL1 renal risk variant genotyping, the GFRNMR test, KidneyIntelX and IntelxDKD, NaviDKD, PromarkerD, the RenaDx Comprehensive Renal Disease Panel, RenalVysion, RenaXome, and transdermal fluorescent pyrazine agents for measuring glomerular filtration rate. CPT code 0105U is not covered for KidneyIntelX, 0407U for IntelxDKD, 0259U for GFRNMR, 0355U for APOL1 genotyping, 0384U and 0385U for NaviDKD and PromarkerD, 0628U for the RenaDx panel, 0653U for RenaXome, and 0602T and 0603T for the transdermal GFR system, for the indications listed. RenalVysion has no specific CPT codes in the policy.
Aetna · Identified Aug 13, 2026Medium impact
Crit-Line In-Line Monitor (CPB 0373, reviewed 2026-05-26)
Aetna considers the Crit-Line In-Line Monitor experimental, investigational, or unproven for monitoring hematocrit and oxygen saturation of members. The policy states that the monitor's effectiveness in avoiding intra-dialytic morbid events, in preventing ischemia due to intra-dialytic hypoxia, and in determining access re-circulations has not been proven. The policy lists no specific CPT or HCPCS code for the Crit-Line In-Line Monitor.
Aetna · Identified Aug 12, 2026Medium impact
Automated Ambulatory Blood Pressure Monitoring (CPB 0025, reviewed 2026-03-12)
Aetna considers automated ambulatory blood pressure monitoring medically necessary when a member meets one of the listed criteria: at least two elevated office readings taken on separate days to identify 'white coat' hypertension; episodic hypertension with symptoms suggesting an adrenal tumor and repeatedly normal office readings; hypotensive symptoms or syncope thought related to antihypertensive medications; syncope evaluated with a 24-hour Holter monitor; nocturnal angina; resistant hypertension before an invasive investigation for secondary causes; or autosomal dominant polycystic kidney disease in children and young adults 30 years of age or younger. Monitoring for less than 24 hours or more than 3 days is not considered medically necessary, and repeat testing is not generally necessary more often than every 6 months. Aetna considers the use experimental, investigational, or unproven for heart failure, for pregnant women who do not meet the criteria, for diagnosing malignant hypertension, for members with an irregular cardiac rhythm such as atrial fibrillation, for routine monitoring to establish a hypertension diagnosis or evaluate treatment response, and for routine use before continuous positive airway pressure (CPAP) therapy.
Presbyterian Health Plan · Identified Jul 31, 2026Medium impact
2026 July Network Connection
CPT 90785 (interactive complexity) may be billed only as an add-on code that accompanies an eligible primary psychiatric service, and only when its specific criteria and requirements are met. Medical records must clearly support CPT 90785 by describing specific communication challenges, challenges affecting clinical interaction, the interactive methods used, and why standard communication approaches were insufficient, and claims submitted without adequate documentation may be subject to audit or review with payment adjusted if billing requirements are not met. Nail pathogen panel claims should be supported by clear clinical indication and medical necessity, prior testing and treatment history, a valid signed provider order specifying test type, and accurate diagnosis coding, and the Presbyterian Program Integrity Department performs random claims validation audits.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Erythropoiesis-Stimulating Agents
Epogen (epoetin alfa), Procrit (epoetin alfa), and Retacrit (epoetin alfa-epbx) are considered medically necessary for anemia related to zidovudine therapy in HIV-infected individuals, anemia in non-myeloid malignancies caused by concomitantly administered chemotherapy, anemia in individuals scheduled for elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions, and anemia associated with chronic kidney disease. Aranesp (darbepoetin alfa) is considered medically necessary for anemia associated with chronic kidney disease, including individuals on dialysis and not on dialysis, and for anemia in non-myeloid malignancies caused by concomitantly administered chemotherapy. The 09/09/2025 revision updated the indications descriptions and added that services related to delivery or administration of a medication determined to be not medically necessary are also considered not medically necessary.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Continuous Arteriovenous Hemofiltration
Continuous renal replacement therapy may be considered medically necessary as supportive treatment for acute renal failure. CPT 90945 and 90947 cover dialysis procedures other than hemodialysis, including hemofiltration and other continuous renal replacement therapies. The policy was reviewed on 01/14/2026 with its policy statement unchanged, and ICD-9 diagnosis codes were removed from the code reference.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Allogeneic Pancreas Transplant
From the 2026-02-10 review of Blue Cross & Blue Shield of Mississippi's allogeneic pancreas transplant policy, which updated the policy description with new transplant data and left the policy statements unchanged. No benefits are provided for a covered transplant procedure unless the member receives prior authorization through case management from Blue Cross & Blue Shield of Mississippi. Combined pancreas-kidney transplant, pancreas after prior kidney transplant, pancreas transplant alone and pancreas retransplant may be considered medically necessary in the specific situations the policy lists, and all other pancreas transplants are investigational.

Watch N19

Get one email when a payer policy names N19, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code N19?

There are 12 tracked policy changes affecting code N19, including updates from Harvard Pilgrim Health Care, Horizon BCBS NJ, Capital Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code N19?

Payers that have issued tracked updates for code N19 include: Harvard Pilgrim Health Care, Horizon BCBS NJ, Capital Blue Cross, Aetna, Presbyterian Health Plan, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code N19 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code N19. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code N19?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Change in denial process for lack of prior authorization

Statin Use in Persons with Diabetes (SUPD)

AB2026-04-002 Medicare only

Selected Kidney Function Tests (CPB 0775, reviewed 2026-10-28)

Cardiovascular Monitoring Equipment for Home Use: Pulse, Blood Pressure, Telemonitors, and Pacemaker Monitors (CPB 0548, reviewed 2026-08-21)

Selected Kidney Function Tests (CPB 0775, reviewed 2026-07-31)

Crit-Line In-Line Monitor (CPB 0373, reviewed 2026-05-26)

Automated Ambulatory Blood Pressure Monitoring (CPB 0025, reviewed 2026-03-12)

2026 July Network Connection

Erythropoiesis-Stimulating Agents

Continuous Arteriovenous Hemofiltration

Allogeneic Pancreas Transplant

What insurance policy changes affect code N19?

Which payers have updated policy for code N19?

How do I get notified when code N19 policy changes?

Why do payers change policies for code N19?